17.38
Novocure Ltd stock is traded at $17.38, with a volume of 1.00M.
It is down -0.34% in the last 24 hours and up +2.54% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$17.44
Open:
$17.52
24h Volume:
1.00M
Relative Volume:
1.16
Market Cap:
$2.02B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-12.41
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-4.24%
1M Performance:
+2.54%
6M Performance:
-0.34%
1Y Performance:
+7.75%
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NVCR
Novocure Ltd
|
17.38 | 2.02B | 577.74M | -149.78M | -78.21M | -1.40 |
![]()
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-20-23 | Resumed | JP Morgan | Neutral |
Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-04-23 | Initiated | SVB Securities | Outperform |
Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
May-16-22 | Initiated | H.C. Wainwright | Buy |
Feb-08-22 | Initiated | Loop Capital | Buy |
Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-20-22 | Upgrade | Truist | Hold → Buy |
Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
Jan-25-21 | Reiterated | Piper Sandler | Overweight |
Sep-23-20 | Initiated | Northland Capital | Outperform |
Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-17-20 | Downgrade | Truist | Buy → Hold |
Jun-01-20 | Resumed | Oppenheimer | Perform |
May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jul-16-18 | Initiated | Evercore ISI | Outperform |
Apr-18-18 | Reiterated | Mizuho | Buy |
Feb-23-18 | Reiterated | Mizuho | Buy |
May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
Jul-29-16 | Reiterated | Wedbush | Outperform |
Jan-19-16 | Initiated | Barclays | Underweight |
Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 20.62, Down -3.28 - DWinneX
Envestnet Asset Management Inc. Buys New Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
Mariner LLC Acquires Shares of 8,631 NovoCure Limited (NASDAQ:NVCR) - Defense World
Comparing Meihua International Medical Technologies (NASDAQ:MHUA) & NovoCure (NASDAQ:NVCR) - Defense World
Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com
What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News
Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st
H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada
NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com
Why NovoCure Stock Skyrocketed This Week - Yahoo Finance
H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com
NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey
NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World
NovoCure (NASDAQ:NVCR) Shares Gap Up After Earnings Beat - Defense World
NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune
Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks
NovoCure (NVCR) Stock Rises on Strong Quarterly Earnings - GuruFocus
NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges - TipRanks
Novocure (NVCR) Sees Early Revenue from Lung Cancer Treatments | NVCR Stock News - GuruFocus
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - Benzinga
Novocure’s device for metastatic NSCLC treatment gains CE Mark - MSN
NovoCure (NVCR) Reports Strong Q1 Revenue Growth Amid Optune Lua Expansion - GuruFocus
Stocks of NovoCure Ltd (NVCR) are poised to climb above their peers - Sete News
NovoCure Surpasses Q1 Expectations - Mitrade
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
NovoCure Surpasses Q1 Expectations - The Motley Fool
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats E - GuruFocus
Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com India
Novocure Reports First Quarter 2025 Financial Results | NVCR Sto - GuruFocus
Novocure (NVCR) Surpasses Q1 Revenue Projections, Reports $154.9 - GuruFocus
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats Estimate, Revenue of $155 Million Exceeds Expectations - GuruFocus
Novocure Reports First Quarter 2025 Financial Results - TradingView
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025 - TipRanks
NovoCure's Earnings: A Preview - Benzinga
Novocure (NVCR) to Showcase Key PANOVA-3 Trial Findings at ASCO 2025 | NVCR Stock News - GuruFocus
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical T - GuruFocus
Novocure price target lowered to $34 from $42 at Piper Sandler - TipRanks
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):